Cytophage Technologies Announces Corporate Restructuring
WINNIPEG — February 19, 2026 — Leads & Copy —
Cytophage Technologies Ltd. (TSXV: CYTO; FSE: 70G) has announced a corporate restructuring aimed at streamlining operations, cutting costs, and preserving financial resources. The company will focus on strategic projects with near-term revenue potential.
The restructuring involves a workforce reduction at Cytophage Technologies Inc., its wholly owned operating subsidiary, through terminations and layoffs. This will lead to the suspension of longer-term, non-core projects that do not offer immediate revenue prospects.
According to Tom Wellner, Chair of the Company’s board of directors, the decision to impact employees was not taken lightly. He stated that the company is grateful for the dedication and contributions of the departing colleagues and that the restructuring is necessary to align resources with high-priority opportunities and ensure long-term sustainability.
Cytophage Technologies is a biotechnology company focused on bacteriophage research, product development, and commercialization. Bacteriophages are viruses that infect and kill bacteria. The company aims to improve these natural bacteria killers through environmental and genetic modifications, offering safe and toxin-free solutions to large markets, initially focusing on animal health.
Cytophage is a bacteriophage manufacturer in Canada and is working to address antibiotic resistance. The World Health Organization (WHO) predicts that antimicrobial resistance will be the leading cause of human mortality by 2050. Many countries have banned or limited preventative antibiotic use in animal production, and consumers worldwide are demanding organic and antibiotic-free products.
Cytophage is using its technology to advance products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.
For more information about Cytophage Technologies and its work in bacteriophage therapy, visit www.cytophage.com.
Source: Cytophage Technologies Ltd.
Share this story:
